ID   KPCA_HUMAN              Reviewed;         672 AA.
AC   P17252; B5BU22; Q15137; Q32M72; Q96RE4;
DT   01-AUG-1990, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 4.
DT   12-APR-2017, entry version 202.
DE   RecName: Full=Protein kinase C alpha type;
DE            Short=PKC-A;
DE            Short=PKC-alpha;
DE            EC=2.7.11.13;
GN   Name=PRKCA; Synonyms=PKCA, PRKACA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT ILE-568.
RC   TISSUE=Blood;
RX   PubMed=2336401; DOI=10.1093/nar/18.8.2183;
RA   Finkenzeller G., Marme D., Hug H.;
RT   "Sequence of human protein kinase C alpha.";
RL   Nucleic Acids Res. 18:2183-2183(1990).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568.
RX   PubMed=19054851; DOI=10.1038/nmeth.1273;
RA   Goshima N., Kawamura Y., Fukumoto A., Miura A., Honma R., Satoh R.,
RA   Wakamatsu A., Yamamoto J., Kimura K., Nishikawa T., Andoh T., Iida Y.,
RA   Ishikawa K., Ito E., Kagawa N., Kaminaga C., Kanehori K., Kawakami B.,
RA   Kenmochi K., Kimura R., Kobayashi M., Kuroita T., Kuwayama H.,
RA   Maruyama Y., Matsuo K., Minami K., Mitsubori M., Mori M.,
RA   Morishita R., Murase A., Nishikawa A., Nishikawa S., Okamoto T.,
RA   Sakagami N., Sakamoto Y., Sasaki Y., Seki T., Sono S., Sugiyama A.,
RA   Sumiya T., Takayama T., Takayama Y., Takeda H., Togashi T., Yahata K.,
RA   Yamada H., Yanagisawa Y., Endo Y., Imamoto F., Kisu Y., Tanaka S.,
RA   Isogai T., Imai J., Watanabe S., Nomura N.;
RT   "Human protein factory for converting the transcriptome into an in
RT   vitro-expressed proteome.";
RL   Nat. Methods 5:1011-1017(2008).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND VARIANT ILE-568.
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT ILE-568.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 15-445.
RX   PubMed=1714454;
RA   McSwine-Kennick R.L., McKeegan E.M., Johnson M.D., Morin M.J.;
RT   "Phorbol diester-induced alterations in the expression of protein
RT   kinase C isozymes and their mRNAs. Analysis in wild-type and phorbol
RT   diester-resistant HL-60 cell clones.";
RL   J. Biol. Chem. 266:15135-15143(1991).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-57.
RA   Haridasse V., Hackenbruck J., Glazer R.I.;
RT   "Homo sapiens protein kinase C alpha 5-flanking sequence.";
RL   Submitted (JUN-2001) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   PROTEIN SEQUENCE OF 2-19.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A.,
RA   Thomas G.R., Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass
RT   spectrometric identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [9]
RP   FUNCTION IN APOPTOSIS, AND SUBCELLULAR LOCATION.
RX   PubMed=9738012; DOI=10.1074/jbc.273.39.25436;
RA   Ruvolo P.P., Deng X., Carr B.K., May W.S.;
RT   "A functional role for mitochondrial protein kinase Calpha in Bcl2
RT   phosphorylation and suppression of apoptosis.";
RL   J. Biol. Chem. 273:25436-25442(1998).
RN   [10]
RP   FUNCTION IN INFLAMMATORY RESPONSE.
RX   PubMed=9830023; DOI=10.1074/jbc.273.49.32787;
RA   St-Denis A., Chano F., Tremblay P., St-Pierre Y., Descoteaux A.;
RT   "Protein kinase C-alpha modulates lipopolysaccharide-induced functions
RT   in a murine macrophage cell line.";
RL   J. Biol. Chem. 273:32787-32792(1998).
RN   [11]
RP   FUNCTION IN INFLAMMATORY RESPONSE.
RX   PubMed=9873035; DOI=10.1074/jbc.274.2.939;
RA   Han Y., Meng T., Murray N.R., Fields A.P., Brasier A.R.;
RT   "Interleukin-1-induced nuclear factor-kappaB-IkappaBalpha
RT   autoregulatory feedback loop in hepatocytes. A role for protein kinase
RT   calpha in post-transcriptional regulation of ikappabalpha
RT   resynthesis.";
RL   J. Biol. Chem. 274:939-947(1999).
RN   [12]
RP   FUNCTION IN APOPTOSIS.
RX   PubMed=9927633;
RA   Shen L., Dean N.M., Glazer R.I.;
RT   "Induction of p53-dependent, insulin-like growth factor-binding
RT   protein-3-mediated apoptosis in glioblastoma multiforme cells by a
RT   protein kinase Calpha antisense oligonucleotide.";
RL   Mol. Pharmacol. 55:396-402(1999).
RN   [13]
RP   FUNCTION IN CELL CYCLE PROGRESSION.
RX   PubMed=10848585; DOI=10.1128/MCB.20.13.4580-4590.2000;
RA   Besson A., Yong V.W.;
RT   "Involvement of p21(Waf1/Cip1) in protein kinase C alpha-induced cell
RT   cycle progression.";
RL   Mol. Cell. Biol. 20:4580-4590(2000).
RN   [14]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=11909826; DOI=10.1161/01.RES.0000012503.30315.E8;
RA   Wang A., Nomura M., Patan S., Ware J.A.;
RT   "Inhibition of protein kinase Calpha prevents endothelial cell
RT   migration and vascular tube formation in vitro and myocardial
RT   neovascularization in vivo.";
RL   Circ. Res. 90:609-616(2002).
RN   [15]
RP   INTERACTION WITH ADAP1.
RX   PubMed=12893243; DOI=10.1016/S0006-291X(03)01187-2;
RA   Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D.,
RA   Wakefield R.I.D., Johannes F.-J., Aitken A.;
RT   "Centaurin-alpha(1) associates with and is phosphorylated by isoforms
RT   of protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 307:459-465(2003).
RN   [16]
RP   FUNCTION IN PLATELET AGGREGATION.
RX   PubMed=12724315; DOI=10.1074/jbc.M212407200;
RA   Tabuchi A., Yoshioka A., Higashi T., Shirakawa R., Nishioka H.,
RA   Kita T., Horiuchi H.;
RT   "Direct demonstration of involvement of protein kinase Calpha in the
RT   Ca2+-induced platelet aggregation.";
RL   J. Biol. Chem. 278:26374-26379(2003).
RN   [17]
RP   FUNCTION IN PHOSPHORYLATION OF TNNT2/CTNT.
RX   PubMed=12832403; DOI=10.1074/jbc.M306325200;
RA   Sumandea M.P., Pyle W.G., Kobayashi T., de Tombe P.P., Solaro R.J.;
RT   "Identification of a functionally critical protein kinase C
RT   phosphorylation residue of cardiac troponin T.";
RL   J. Biol. Chem. 278:35135-35144(2003).
RN   [18]
RP   FUNCTION IN KIT SIGNALING.
RX   PubMed=15526160; DOI=10.1007/s00018-004-4189-6;
RA   Ronnstrand L.;
RT   "Signal transduction via the stem cell factor receptor/c-Kit.";
RL   Cell. Mol. Life Sci. 61:2535-2548(2004).
RN   [19]
RP   FUNCTION IN PHOSPHORYLATION OF TRPC1.
RX   PubMed=15016832; DOI=10.1074/jbc.M313975200;
RA   Ahmmed G.U., Mehta D., Vogel S., Holinstat M., Paria B.C.,
RA   Tiruppathi C., Malik A.B.;
RT   "Protein kinase Calpha phosphorylates the TRPC1 channel and regulates
RT   store-operated Ca2+ entry in endothelial cells.";
RL   J. Biol. Chem. 279:20941-20949(2004).
RN   [20]
RP   INTERACTION WITH PICK1.
RX   PubMed=15247289; DOI=10.1074/jbc.M404499200;
RA   Dev K.K., Nakanishi S., Henley J.M.;
RT   "The PDZ domain of PICK1 differentially accepts protein kinase C-alpha
RT   and GluR2 as interacting ligands.";
RL   J. Biol. Chem. 279:41393-41397(2004).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF CSPG4, AND INTERACTION WITH CSPG4.
RX   PubMed=15504744; DOI=10.1074/jbc.M411045200;
RA   Makagiansar I.T., Williams S., Dahlin-Huppe K., Fukushi J.,
RA   Mustelin T., Stallcup W.B.;
RT   "Phosphorylation of NG2 proteoglycan by protein kinase C-alpha
RT   regulates polarized membrane distribution and cell motility.";
RL   J. Biol. Chem. 279:55262-55270(2004).
RN   [22]
RP   REVIEW ON ROLE IN KIT SIGNALING.
RX   PubMed=16129412; DOI=10.1016/j.bbrc.2005.08.055;
RA   Roskoski R. Jr.;
RT   "Signaling by Kit protein-tyrosine kinase--the stem cell factor
RT   receptor.";
RL   Biochem. Biophys. Res. Commun. 337:1-13(2005).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [24]
RP   INTERACTION WITH TRIM41.
RX   PubMed=17893151; DOI=10.1074/jbc.M703320200;
RA   Chen D., Gould C., Garza R., Gao T., Hampton R.Y., Newton A.C.;
RT   "Amplitude control of protein kinase C by RINCK, a novel E3 ubiquitin
RT   ligase.";
RL   J. Biol. Chem. 282:33776-33787(2007).
RN   [25]
RP   FUNCTION IN ANGIOGENESIS.
RX   PubMed=18056764; DOI=10.1093/cvr/cvm085;
RA   Xu H., Czerwinski P., Hortmann M., Sohn H.Y., Foerstermann U., Li H.;
RT   "Protein kinase C alpha promotes angiogenic activity of human
RT   endothelial cells via induction of vascular endothelial growth
RT   factor.";
RL   Cardiovasc. Res. 78:349-355(2008).
RN   [26]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-638 AND SER-651, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [29]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [30]
RP   FUNCTION.
RX   PubMed=19176525; DOI=10.1074/jbc.M808719200;
RA   Yamasaki T., Takahashi A., Pan J., Yamaguchi N., Yokoyama K.K.;
RT   "Phosphorylation of activation transcription factor-2 at serine 121 by
RT   protein kinase c controls c-Jun-mediated activation of
RT   transcription.";
RL   J. Biol. Chem. 284:8567-8581(2009).
RN   [31]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [32]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-628, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [33]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226 AND THR-638, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [34]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [35]
RP   FUNCTION IN PHOSPHORYLATION OF EIF4G1.
RX   PubMed=21576361; DOI=10.1128/MCB.05589-11;
RA   Dobrikov M., Dobrikova E., Shveygert M., Gromeier M.;
RT   "Phosphorylation of eukaryotic translation initiation factor 4G1
RT   (eIF4G1) by protein kinase C{alpha} regulates eIF4G1 binding to
RT   Mnk1.";
RL   Mol. Cell. Biol. 31:2947-2959(2011).
RN   [36]
RP   REVIEW ON FUNCTION, AND REVIEW ON ENZYME REGULATION.
RX   PubMed=12417014; DOI=10.1093/oxfordjournals.jbchem.a003272;
RA   Nakashima S.;
RT   "Protein kinase C alpha (PKC alpha): regulation and biological
RT   function.";
RL   J. Biochem. 132:669-675(2002).
RN   [37]
RP   REVIEW ON FUNCTION.
RX   PubMed=19969380; DOI=10.1016/j.tips.2009.10.006;
RA   Konopatskaya O., Poole A.W.;
RT   "Protein kinase Calpha: disease regulator and therapeutic target.";
RL   Trends Pharmacol. Sci. 31:8-14(2010).
RN   [38]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [39]
RP   FUNCTION IN CELL MIGRATION, AND SUBCELLULAR LOCATION.
RX   PubMed=23990668; DOI=10.1093/jnci/djt224;
RA   Evensen N.A., Kuscu C., Nguyen H.L., Zarrabi K., Dufour A., Kadam P.,
RA   Hu Y.J., Pulkoski-Gross A., Bahou W.F., Zucker S., Cao J.;
RT   "Unraveling the role of KIAA1199, a novel endoplasmic reticulum
RT   protein, in cancer cell migration.";
RL   J. Natl. Cancer Inst. 105:1402-1416(2013).
RN   [40]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-10 AND SER-226, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-226; THR-638 AND
RP   SER-657, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [42]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) OF 320-672 IN COMPLEX WITH
RP   INHIBITOR.
RX   PubMed=19827831; DOI=10.1021/jm901108b;
RA   Wagner J., von Matt P., Sedrani R., Albert R., Cooke N., Ehrhardt C.,
RA   Geiser M., Rummel G., Stark W., Strauss A., Cowan-Jacob S.W.,
RA   Beerli C., Weckbecker G., Evenou J.P., Zenke G., Cottens S.;
RT   "Discovery of 3-(1H-indol-3-yl)-4-[2-(4-methylpiperazin-1-
RT   yl)quinazolin-4-yl]pyrrole-2,5-dione (AEB071), a potent and selective
RT   inhibitor of protein kinase C isotypes.";
RL   J. Med. Chem. 52:6193-6196(2009).
RN   [43]
RP   STRUCTURE BY NMR OF 88-169.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the second phorbol esters/diacylglycerol
RT   binding domain of human protein kinase C alpha type.";
RL   Submitted (APR-2008) to the PDB data bank.
RN   [44]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-98; ASN-467 AND VAL-489.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium-activated, phospholipid- and diacylglycerol
CC       (DAG)-dependent serine/threonine-protein kinase that is involved
CC       in positive and negative regulation of cell proliferation,
CC       apoptosis, differentiation, migration and adhesion, tumorigenesis,
CC       cardiac hypertrophy, angiogenesis, platelet function and
CC       inflammation, by directly phosphorylating targets such as RAF1,
CC       BCL2, CSPG4, TNNT2/CTNT, or activating signaling cascade involving
CC       MAPK1/3 (ERK1/2) and RAP1GAP. Involved in cell proliferation and
CC       cell growth arrest by positive and negative regulation of the cell
CC       cycle. Can promote cell growth by phosphorylating and activating
CC       RAF1, which mediates the activation of the MAPK/ERK signaling
CC       cascade, and/or by up-regulating CDKN1A, which facilitates active
CC       cyclin-dependent kinase (CDK) complex formation in glioma cells.
CC       In intestinal cells stimulated by the phorbol ester PMA, can
CC       trigger a cell cycle arrest program which is associated with the
CC       accumulation of the hyper-phosphorylated growth-suppressive form
CC       of RB1 and induction of the CDK inhibitors CDKN1A and CDKN1B.
CC       Exhibits anti-apoptotic function in glioma cells and protects them
CC       from apoptosis by suppressing the p53/TP53-mediated activation of
CC       IGFBP3, and in leukemia cells mediates anti-apoptotic action by
CC       phosphorylating BCL2. During macrophage differentiation induced by
CC       macrophage colony-stimulating factor (CSF1), is translocated to
CC       the nucleus and is associated with macrophage development. After
CC       wounding, translocates from focal contacts to lamellipodia and
CC       participates in the modulation of desmosomal adhesion. Plays a
CC       role in cell motility by phosphorylating CSPG4, which induces
CC       association of CSPG4 with extensive lamellipodia at the cell
CC       periphery and polarization of the cell accompanied by increases in
CC       cell motility. Is highly expressed in a number of cancer cells
CC       where it can act as a tumor promoter and is implicated in
CC       malignant phenotypes of several tumors such as gliomas and breast
CC       cancers. Negatively regulates myocardial contractility and
CC       positively regulates angiogenesis, platelet aggregation and
CC       thrombus formation in arteries. Mediates hypertrophic growth of
CC       neonatal cardiomyocytes, in part through a MAPK1/3 (ERK1/2)-
CC       dependent signaling pathway, and upon PMA treatment, is required
CC       to induce cardiomyocyte hypertrophy up to heart failure and death,
CC       by increasing protein synthesis, protein-DNA ratio and cell
CC       surface area. Regulates cardiomyocyte function by phosphorylating
CC       cardiac troponin T (TNNT2/CTNT), which induces significant
CC       reduction in actomyosin ATPase activity, myofilament calcium
CC       sensitivity and myocardial contractility. In angiogenesis, is
CC       required for full endothelial cell migration, adhesion to
CC       vitronectin (VTN), and vascular endothelial growth factor A
CC       (VEGFA)-dependent regulation of kinase activation and vascular
CC       tube formation. Involved in the stabilization of VEGFA mRNA at
CC       post-transcriptional level and mediates VEGFA-induced cell
CC       proliferation. In the regulation of calcium-induced platelet
CC       aggregation, mediates signals from the CD36/GP4 receptor for
CC       granule release, and activates the integrin heterodimer ITGA2B-
CC       ITGB3 through the RAP1GAP pathway for adhesion. During response to
CC       lipopolysaccharides (LPS), may regulate selective LPS-induced
CC       macrophage functions involved in host defense and inflammation.
CC       But in some inflammatory responses, may negatively regulate NF-
CC       kappa-B-induced genes, through IL1A-dependent induction of NF-
CC       kappa-B inhibitor alpha (NFKBIA/IKBA). Upon stimulation with 12-O-
CC       tetradecanoylphorbol-13-acetate (TPA), phosphorylates EIF4G1,
CC       which modulates EIF4G1 binding to MKNK1 and may be involved in the
CC       regulation of EIF4E phosphorylation. Phosphorylates KIT, leading
CC       to inhibition of KIT activity. Phosphorylates ATF2 which promotes
CC       cooperation between ATF2 and JUN, activating transcription.
CC       {ECO:0000269|PubMed:10848585, ECO:0000269|PubMed:11909826,
CC       ECO:0000269|PubMed:12724315, ECO:0000269|PubMed:12832403,
CC       ECO:0000269|PubMed:15016832, ECO:0000269|PubMed:15504744,
CC       ECO:0000269|PubMed:15526160, ECO:0000269|PubMed:18056764,
CC       ECO:0000269|PubMed:19176525, ECO:0000269|PubMed:21576361,
CC       ECO:0000269|PubMed:23990668, ECO:0000269|PubMed:9738012,
CC       ECO:0000269|PubMed:9830023, ECO:0000269|PubMed:9873035,
CC       ECO:0000269|PubMed:9927633}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000250|UniProtKB:P05696};
CC       Note=Binds 3 Ca(2+) ions per subunit. The ions are bound to the C2
CC       domain. {ECO:0000250|UniProtKB:P05696};
CC   -!- ENZYME REGULATION: Classical (or conventional) PKCs (PRKCA, PRKCB
CC       and PRKCG) are activated by calcium and diacylglycerol (DAG) in
CC       the presence of phosphatidylserine. Three specific sites; Thr-497
CC       (activation loop of the kinase domain), Thr-638 (turn motif) and
CC       Ser-657 (hydrophobic region), need to be phosphorylated for its
CC       full activation.
CC   -!- SUBUNIT: Recruited in a circadian manner into a nuclear complex
CC       which also includes BMAL1 and RACK1 (By similarity). Interacts
CC       with ADAP1/CENTA1, CSPG4 and PRKCABP. Binds to SDPR in the
CC       presence of phosphatidylserine. Interacts with PICK1 (via PDZ
CC       domain). Interacts with TRIM41. {ECO:0000250,
CC       ECO:0000269|PubMed:12893243, ECO:0000269|PubMed:15247289,
CC       ECO:0000269|PubMed:15504744, ECO:0000269|PubMed:17893151,
CC       ECO:0000269|PubMed:19827831}.
CC   -!- INTERACTION:
CC       P00533:EGFR; NbExp=2; IntAct=EBI-1383528, EBI-297353;
CC       Q9UBN7:HDAC6; NbExp=2; IntAct=EBI-1383528, EBI-301697;
CC       Q24008:inaD (xeno); NbExp=2; IntAct=EBI-1383528, EBI-195326;
CC       P31431:SDC4; NbExp=2; IntAct=EBI-1383528, EBI-3913237;
CC       P0CG48:UBC; NbExp=2; IntAct=EBI-1383528, EBI-3390054;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:23990668}.
CC       Cell membrane {ECO:0000269|PubMed:23990668}; Peripheral membrane
CC       protein {ECO:0000305|PubMed:23990668}. Mitochondrion membrane
CC       {ECO:0000269|PubMed:9738012}; Peripheral membrane protein
CC       {ECO:0000305|PubMed:9738012}. Nucleus
CC       {ECO:0000250|UniProtKB:P20444}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X52479; CAA36718.1; -; mRNA.
DR   EMBL; AB451258; BAG70072.1; -; mRNA.
DR   EMBL; AB451383; BAG70197.1; -; mRNA.
DR   EMBL; AC005918; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC005988; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006263; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC006947; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC009452; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC060796; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471099; EAW89014.1; -; Genomic_DNA.
DR   EMBL; BC109273; AAI09274.1; -; mRNA.
DR   EMBL; BC109274; AAI09275.1; -; mRNA.
DR   EMBL; M22199; AAA60098.1; -; mRNA.
DR   EMBL; AF395829; AAK84184.1; -; Genomic_DNA.
DR   CCDS; CCDS11664.1; -.
DR   PIR; S09496; KIHUCA.
DR   RefSeq; NP_002728.1; NM_002737.2.
DR   UniGene; Hs.531704; -.
DR   UniGene; Hs.708867; -.
DR   PDB; 2ELI; NMR; -; A=93-169.
DR   PDB; 3IW4; X-ray; 2.80 A; A/B/C=320-672.
DR   PDB; 4DNL; X-ray; 1.90 A; A=155-293.
DR   PDB; 4RA4; X-ray; 2.63 A; A=318-672.
DR   PDBsum; 2ELI; -.
DR   PDBsum; 3IW4; -.
DR   PDBsum; 4DNL; -.
DR   PDBsum; 4RA4; -.
DR   ProteinModelPortal; P17252; -.
DR   SMR; P17252; -.
DR   BioGrid; 111564; 153.
DR   DIP; DIP-531N; -.
DR   IntAct; P17252; 33.
DR   MINT; MINT-140812; -.
DR   STRING; 9606.ENSP00000408695; -.
DR   BindingDB; P17252; -.
DR   ChEMBL; CHEMBL299; -.
DR   DrugBank; DB08846; Ellagic Acid.
DR   DrugBank; DB05013; Ingenol Mebutate.
DR   DrugBank; DB00144; Phosphatidyl serine.
DR   DrugBank; DB00675; Tamoxifen.
DR   DrugBank; DB00163; Vitamin E.
DR   GuidetoPHARMACOLOGY; 1482; -.
DR   iPTMnet; P17252; -.
DR   PhosphoSitePlus; P17252; -.
DR   SwissPalm; P17252; -.
DR   BioMuta; PRKCA; -.
DR   DMDM; 317373571; -.
DR   EPD; P17252; -.
DR   MaxQB; P17252; -.
DR   PaxDb; P17252; -.
DR   PeptideAtlas; P17252; -.
DR   PRIDE; P17252; -.
DR   DNASU; 5578; -.
DR   Ensembl; ENST00000413366; ENSP00000408695; ENSG00000154229.
DR   GeneID; 5578; -.
DR   KEGG; hsa:5578; -.
DR   UCSC; uc002jfp.2; human.
DR   CTD; 5578; -.
DR   DisGeNET; 5578; -.
DR   GeneCards; PRKCA; -.
DR   HGNC; HGNC:9393; PRKCA.
DR   HPA; CAB003844; -.
DR   HPA; CAB016290; -.
DR   HPA; HPA006563; -.
DR   HPA; HPA006564; -.
DR   MIM; 176960; gene.
DR   neXtProt; NX_P17252; -.
DR   OpenTargets; ENSG00000154229; -.
DR   PharmGKB; PA33759; -.
DR   eggNOG; KOG0694; Eukaryota.
DR   eggNOG; ENOG410XNPH; LUCA.
DR   GeneTree; ENSGT00820000126964; -.
DR   HOGENOM; HOG000233022; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; P17252; -.
DR   KO; K02677; -.
DR   OMA; QSKKDMI; -.
DR   OrthoDB; EOG091G0QRS; -.
DR   PhylomeDB; P17252; -.
DR   TreeFam; TF351133; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-111933; Calmodulin induced events.
DR   Reactome; R-HSA-114516; Disinhibition of SNARE formation.
DR   Reactome; R-HSA-1250196; SHC1 events in ERBB2 signaling.
DR   Reactome; R-HSA-1433557; Signaling by SCF-KIT.
DR   Reactome; R-HSA-1433559; Regulation of KIT signaling.
DR   Reactome; R-HSA-2179392; EGFR Transactivation by Gastrin.
DR   Reactome; R-HSA-2514859; Inactivation, recovery and regulation of the phototransduction cascade.
DR   Reactome; R-HSA-3000170; Syndecan interactions.
DR   Reactome; R-HSA-399997; Acetylcholine regulates insulin secretion.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-416993; Trafficking of GluR2-containing AMPA receptors.
DR   Reactome; R-HSA-418597; G alpha (z) signalling events.
DR   Reactome; R-HSA-4419969; Depolymerisation of the Nuclear Lamina.
DR   Reactome; R-HSA-450520; HuR (ELAVL1) binds and stabilizes mRNA.
DR   Reactome; R-HSA-5099900; WNT5A-dependent internalization of FZD4.
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   Reactome; R-HSA-76005; Response to elevated platelet cytosolic Ca2+.
DR   Reactome; R-HSA-8853659; RET signaling.
DR   SignaLink; P17252; -.
DR   SIGNOR; P17252; -.
DR   ChiTaRS; PRKCA; human.
DR   EvolutionaryTrace; P17252; -.
DR   GeneWiki; PKC_alpha; -.
DR   GenomeRNAi; 5578; -.
DR   PMAP-CutDB; P17252; -.
DR   PRO; PR:P17252; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000154229; -.
DR   CleanEx; HS_PRKACA; -.
DR   CleanEx; HS_PRKCA; -.
DR   ExpressionAtlas; P17252; baseline and differential.
DR   Genevisible; P17252; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031966; C:mitochondrial membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004698; F:calcium-dependent protein kinase C activity; TAS:Reactome.
DR   GO; GO:0019899; F:enzyme binding; IDA:BHF-UCL.
DR   GO; GO:0035403; F:histone kinase activity (H3-T6 specific); IDA:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004697; F:protein kinase C activity; ISS:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; EXP:Reactome.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0007190; P:activation of adenylate cyclase activity; ISS:BHF-UCL.
DR   GO; GO:0001525; P:angiogenesis; IEA:UniProtKB-KW.
DR   GO; GO:0097190; P:apoptotic signaling pathway; TAS:ProtInc.
DR   GO; GO:0007411; P:axon guidance; TAS:Reactome.
DR   GO; GO:0007155; P:cell adhesion; IEA:UniProtKB-KW.
DR   GO; GO:0002159; P:desmosome assembly; IMP:BHF-UCL.
DR   GO; GO:0038128; P:ERBB2 signaling pathway; TAS:Reactome.
DR   GO; GO:0035408; P:histone H3-T6 phosphorylation; IDA:UniProtKB.
DR   GO; GO:0035556; P:intracellular signal transduction; IBA:GO_Central.
DR   GO; GO:0007077; P:mitotic nuclear envelope disassembly; TAS:Reactome.
DR   GO; GO:0007194; P:negative regulation of adenylate cyclase activity; ISS:BHF-UCL.
DR   GO; GO:0034351; P:negative regulation of glial cell apoptotic process; IMP:UniProtKB.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IBA:GO_Central.
DR   GO; GO:0030168; P:platelet activation; TAS:Reactome.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IMP:UniProtKB.
DR   GO; GO:0043536; P:positive regulation of blood vessel endothelial cell migration; IDA:DFLAT.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; ISS:UniProtKB.
DR   GO; GO:0045785; P:positive regulation of cell adhesion; IMP:UniProtKB.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:UniProtKB.
DR   GO; GO:2000707; P:positive regulation of dense core granule biogenesis; ISS:UniProtKB.
DR   GO; GO:0010595; P:positive regulation of endothelial cell migration; IMP:UniProtKB.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; ISS:UniProtKB.
DR   GO; GO:0031666; P:positive regulation of lipopolysaccharide-mediated signaling pathway; IMP:UniProtKB.
DR   GO; GO:0045651; P:positive regulation of macrophage differentiation; ISS:UniProtKB.
DR   GO; GO:0045931; P:positive regulation of mitotic cell cycle; IMP:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0050796; P:regulation of insulin secretion; TAS:Reactome.
DR   GO; GO:0043488; P:regulation of mRNA stability; TAS:Reactome.
DR   GO; GO:0090330; P:regulation of platelet aggregation; IDA:UniProtKB.
DR   GO; GO:0070555; P:response to interleukin-1; IMP:BHF-UCL.
DR   CDD; cd00029; C1; 2.
DR   CDD; cd05615; STKc_cPKC_alpha; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR034663; cPKC_alpha.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014375; Protein_kinase_C_a/b/g.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 2.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000550; PKC_alpha; 1.
DR   PRINTS; PR00360; C2DOMAIN.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 2.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 2.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 2.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Angiogenesis; Apoptosis; ATP-binding;
KW   Calcium; Cell adhesion; Cell membrane; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Kinase; Membrane; Metal-binding;
KW   Mitochondrion; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Proto-oncogene; Reference proteome; Repeat;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|PubMed:12665801}.
FT   CHAIN         2    672       Protein kinase C alpha type.
FT                                /FTId=PRO_0000055679.
FT   DOMAIN      172    260       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      339    597       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      598    668       AGC-kinase C-terminal.
FT   ZN_FING      36     86       Phorbol-ester/DAG-type 1.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   ZN_FING     101    151       Phorbol-ester/DAG-type 2.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     345    353       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   ACT_SITE    463    463       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   METAL       186    186       Calcium 1; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       187    187       Calcium 1.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       187    187       Calcium 2.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       193    193       Calcium 2.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       246    246       Calcium 1.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       246    246       Calcium 2.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       247    247       Calcium 2; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       248    248       Calcium 1.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       248    248       Calcium 2.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       248    248       Calcium 3.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       252    252       Calcium 3; via carbonyl oxygen.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       254    254       Calcium 1.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   METAL       254    254       Calcium 3.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   BINDING     195    195       Inositol phosphate group.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   BINDING     245    245       Inositol phosphate group.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   BINDING     368    368       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES      10     10       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     226    226       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     319    319       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P05696}.
FT   MOD_RES     497    497       Phosphothreonine; by PDPK1.
FT                                {ECO:0000305}.
FT   MOD_RES     501    501       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P05771}.
FT   MOD_RES     628    628       N6-acetyllysine.
FT                                {ECO:0000244|PubMed:19608861}.
FT   MOD_RES     631    631       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250|UniProtKB:P68403,
FT                                ECO:0000255}.
FT   MOD_RES     638    638       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     651    651       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     657    657       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     658    658       Phosphotyrosine; by SYK. {ECO:0000250}.
FT   VARIANT      98     98       P -> S (in a colorectal adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042301.
FT   VARIANT     467    467       D -> N (in a glioblastoma multiforme
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042302.
FT   VARIANT     489    489       M -> V (in dbSNP:rs34406842).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042303.
FT   VARIANT     568    568       V -> I (in dbSNP:rs6504459).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:19054851,
FT                                ECO:0000269|PubMed:2336401,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_050558.
FT   CONFLICT     50     50       C -> S (in Ref. 6; AAA60098).
FT                                {ECO:0000305}.
FT   TURN         98    100       {ECO:0000244|PDB:2ELI}.
FT   STRAND      105    107       {ECO:0000244|PDB:2ELI}.
FT   STRAND      116    118       {ECO:0000244|PDB:2ELI}.
FT   STRAND      125    127       {ECO:0000244|PDB:2ELI}.
FT   STRAND      129    131       {ECO:0000244|PDB:2ELI}.
FT   STRAND      133    135       {ECO:0000244|PDB:2ELI}.
FT   STRAND      138    140       {ECO:0000244|PDB:2ELI}.
FT   TURN        141    146       {ECO:0000244|PDB:2ELI}.
FT   STRAND      161    169       {ECO:0000244|PDB:4DNL}.
FT   STRAND      172    182       {ECO:0000244|PDB:4DNL}.
FT   STRAND      194    202       {ECO:0000244|PDB:4DNL}.
FT   STRAND      222    230       {ECO:0000244|PDB:4DNL}.
FT   HELIX       233    237       {ECO:0000244|PDB:4DNL}.
FT   STRAND      239    246       {ECO:0000244|PDB:4DNL}.
FT   STRAND      249    251       {ECO:0000244|PDB:4DNL}.
FT   STRAND      254    262       {ECO:0000244|PDB:4DNL}.
FT   HELIX       263    268       {ECO:0000244|PDB:4DNL}.
FT   STRAND      271    276       {ECO:0000244|PDB:4DNL}.
FT   HELIX       282    284       {ECO:0000244|PDB:4DNL}.
FT   HELIX       336    338       {ECO:0000244|PDB:4RA4}.
FT   STRAND      339    350       {ECO:0000244|PDB:4RA4}.
FT   STRAND      352    361       {ECO:0000244|PDB:4RA4}.
FT   STRAND      364    371       {ECO:0000244|PDB:4RA4}.
FT   HELIX       372    377       {ECO:0000244|PDB:4RA4}.
FT   HELIX       381    392       {ECO:0000244|PDB:4RA4}.
FT   STRAND      403    408       {ECO:0000244|PDB:4RA4}.
FT   STRAND      410    417       {ECO:0000244|PDB:4RA4}.
FT   STRAND      422    424       {ECO:0000244|PDB:3IW4}.
FT   HELIX       425    432       {ECO:0000244|PDB:4RA4}.
FT   HELIX       437    456       {ECO:0000244|PDB:4RA4}.
FT   HELIX       466    468       {ECO:0000244|PDB:4RA4}.
FT   STRAND      469    471       {ECO:0000244|PDB:4RA4}.
FT   STRAND      477    479       {ECO:0000244|PDB:4RA4}.
FT   HELIX       502    504       {ECO:0000244|PDB:4RA4}.
FT   HELIX       507    510       {ECO:0000244|PDB:4RA4}.
FT   HELIX       518    533       {ECO:0000244|PDB:4RA4}.
FT   HELIX       543    552       {ECO:0000244|PDB:4RA4}.
FT   HELIX       563    572       {ECO:0000244|PDB:4RA4}.
FT   HELIX       577    579       {ECO:0000244|PDB:4RA4}.
FT   HELIX       587    593       {ECO:0000244|PDB:4RA4}.
FT   HELIX       595    597       {ECO:0000244|PDB:4RA4}.
FT   HELIX       602    606       {ECO:0000244|PDB:4RA4}.
FT   HELIX       642    646       {ECO:0000244|PDB:4RA4}.
FT   HELIX       650    653       {ECO:0000244|PDB:4RA4}.
SQ   SEQUENCE   672 AA;  76750 MW;  9EB157789A062349 CRC64;
     MADVFPGNDS TASQDVANRF ARKGALRQKN VHEVKDHKFI ARFFKQPTFC SHCTDFIWGF
     GKQGFQCQVC CFVVHKRCHE FVTFSCPGAD KGPDTDDPRS KHKFKIHTYG SPTFCDHCGS
     LLYGLIHQGM KCDTCDMNVH KQCVINVPSL CGMDHTEKRG RIYLKAEVAD EKLHVTVRDA
     KNLIPMDPNG LSDPYVKLKL IPDPKNESKQ KTKTIRSTLN PQWNESFTFK LKPSDKDRRL
     SVEIWDWDRT TRNDFMGSLS FGVSELMKMP ASGWYKLLNQ EEGEYYNVPI PEGDEEGNME
     LRQKFEKAKL GPAGNKVISP SEDRKQPSNN LDRVKLTDFN FLMVLGKGSF GKVMLADRKG
     TEELYAIKIL KKDVVIQDDD VECTMVEKRV LALLDKPPFL TQLHSCFQTV DRLYFVMEYV
     NGGDLMYHIQ QVGKFKEPQA VFYAAEISIG LFFLHKRGII YRDLKLDNVM LDSEGHIKIA
     DFGMCKEHMM DGVTTRTFCG TPDYIAPEII AYQPYGKSVD WWAYGVLLYE MLAGQPPFDG
     EDEDELFQSI MEHNVSYPKS LSKEAVSVCK GLMTKHPAKR LGCGPEGERD VREHAFFRRI
     DWEKLENREI QPPFKPKVCG KGAENFDKFF TRGQPVLTPP DQLVIANIDQ SDFEGFSYVN
     PQFVHPILQS AV
//
